Table 1 Clinical profiles of the patients who completed follow-up
Age (years) | Duration (years) | UPDRS part3 | L-DOPA (mg) | LEDD (mg) | |
Patient 1 | 68 | 9 | 31 | 350 | 0 |
Patient 2 | 72 | 3 | 20 | 250 | 0 |
Patient 3 | 69 | 2 | 8 | 100 | 100 |
Patient 4 | 66 | 2 | 19 | 200 | 0 |
Patient 5 | 72 | 2 | 18 | 200 | 0 |
Patient 6 | 66 | 4 | 19 | 300 | 75 |
Patient 7 | 69 | 7 | 17 | 400 | 75 |
Patient 8 | 74 | 8 | 8 | 150 | 50 |
Patient 9 | 68 | 9 | 17 | 200 | 150 |
Patient 10 | 67 | 5 | 13 | 0 | 135 |
Mean ± SD | 69.0 ± 2.7 | 5.1 ± 2.9 | 17.0 ± 6.6 | 215.0 ± 118.0 | 58.5 ± 58.0 |
MMSE | MoCA | PASAT | TMT-A (sec) | TMT-B (sec) | |
Patient 1 | 25 | 20 | 21 | 79 | 420 |
Patient 2 | 29 | 24 | 28 | 69.7 | 238 |
Patient 3 | 27 | 25 | 28 | 39.5 | 159 |
Patient 4 | 28 | 21 | 19 | 48.4 | 151.4 |
Patient 5 | 29 | 23 | 32 | 77.4 | 194.4 |
Patient 6 | 26 | 17 | 18 | 100.6 | 379.8 |
Patient 7 | 25 | 18 | 18 | 65.4 | 420 |
Patient 8 | 26 | 19 | 16 | 53.6 | 107 |
Patient 9 | 25 | 18 | 8 | 56.8 | 167.3 |
Patient 10 | 25 | 16 | 26 | 104.7 | 357 |
Mean ± SD | 26.5 ± 1.6 | 20.1 ± 3.1 | 21.4 ± 7.1 | 69.5 ± 21.4 | 259.4 ± 121.9 |